• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
XOMA

XOMA

XOMA Royalty Corp.

NASDAQHealthcareBiotechnologyUS

USD41.70

+0.01 (+0.02%)

Rating:B

Company Profile

CEO

Owen Hughes Jr.

IPO Date

1986-06-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$41.56

Prev. Close

$41.69

Day Low

$41.56

Day High

$41.73

52W Low

$22.29

52W High

$42.81

Market Cap

$0.52B

Volume

0.07M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

39.5%

Avg Negative

1.8%

Avg Neutral

58.9%

News Feed

Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros's license agreement with Checkmate Pharmaceuticals

GlobeNewsWire·7/15/2021·↓ negative

XOMA Acquires Royalty and Milestone Interest in Checkmate's Vidutolimod (CMP-001) from Kuros Biosciences

GlobeNewsWire·7/15/2021·↑ positive

XOMA Declares Quarterly Preferred Stock Dividends

GlobeNewsWire·6/21/2021·↑ positive

XOMA Licensees to Present Significant Clinical Data at 2021 ASCO Annual Meeting

GlobeNewsWire·5/21/2021·↑ positive

XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program

GlobeNewsWire·5/3/2021·↑ positive

New Preferred Stock IPOs, April 2021

Seeking Alpha·4/27/2021·↑ positive

XOMA's Royalty Portfolio Grows with Addition of Three Royalty Assets

GlobeNewsWire·4/15/2021·↑ positive

XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters' Option

GlobeNewsWire·4/12/2021·↑ positive

XOMA Prices $35 Million Offering of Depositary Shares

GlobeNewsWire·4/6/2021·↓ negative

XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock

GlobeNewsWire·4/5/2021·↑ positive